Sugi Predict

Sugi Predict / Compounds / SCHEMBL503269

SCHEMBL503269

SCHEMBL503269

CCNc1ccc(Br)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ HCAR3 P49019 1/20 0.53
▸ RAB9A P51151 6/20 0.51
▸ PKM P14618 3/20 0.51
▸ ATM Q13315 1/20 0.51
▸ ADRA2A P08913 1/20 0.50
▸ ADRA2B P18089 1/20 0.50
▸ ADRA2C P18825 1/20 0.50
▸ MEN1 O00255 4/20 0.49
▸ MAPT P10636 4/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ LMNA P02545 1/20 0.49
▸ GAA P10253 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2713140 0.98 NPC1 (0.54) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL12963036 0.84 HCAR3 (0.56) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL22795638 0.81 RAB9A (0.61) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL12932912 0.80 NPC1 (0.49) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL7150739 0.80 HCAR3 (0.59) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL15828788 0.79 NPC1 (0.48) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL183600 0.79 HCAR3 (0.57) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL81827 0.77 HCAR3 (0.55) KDM4EALDH1A1HCAR3RAB9AADRA2A
SCHEMBL1060108 0.76 NPC1 (0.49) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1
SCHEMBL182559 0.76 NPC1 (0.53) NPC1SMN1; SMN2KDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619388-A1 CATHEPSIN L INHIBITORS Biofront Therapeutics (Beijing) Co., Ltd. (CN) 2025-09-24 — — EP disclosed
WO-2024140356-A1 CATHEPSIN L INHIBITORS BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-07-04 — — WO disclosed
US-11858905-B1 Cathepsin L inhibitors BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) 2024-01-02 — — US disclosed
CN-116589425-A Cathepsin L inhibitors 百放英库医药科技(北京)有限公司 2023-08-15 — — CN disclosed
EP-3416960-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2021-12-01 — — EP disclosed
EP-3416960-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2021-12-01 — — EP disclosed
CN-108699035-B Novel compounds 特殊治疗有限公司 2021-10-15 — — CN disclosed
WO-2020228756-A1 INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2020-11-19 — — WO disclosed
US-10640498-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2020-05-05 — — US disclosed
US-20190055232-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED (GB) 2019-02-21 — — US disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 — — US disclosed
US-20080242665-A1 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; F. HOFFMANN-LA ROCHE AG (CH) 2008-10-02 — — US disclosed
WO-2008070740-A1 PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE F.HOFFMANN-LA ROCHE AG (CH) 2008-06-12 — — WO disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed
US-7244763-B2 Compounds that modulate PPAR activity and methods of preparation WARNER LAMBERT COMPANY LLC (US) 2007-07-17 — — US disclosed
EP-1620086-A1 COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION Warner-Lambert Company LLC (US) 2006-02-01 — — EP disclosed
US-6875780-B2 Compounds that modulate PPAR activity and methods for their preparation WARNER-LAMBERT COMPANY (US) 2005-04-05 — — US disclosed
WO-2004091604-A1 COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION WARNER-LAMBERT COMPANY LLC (US) 2004-10-28 — — WO disclosed
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation BRATTON LARRY D (US) 2004-10-21 — — US disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10640498-B2 Compounds USP30, USP20, UBQLN1 NPC1 1767/4885SMN1; SMN2 2968/4885KDM4E 945/4885
US-11858905-B1 Cathepsin L inhibitors CTSV, CTSL, CTSB NPC1 84/4885SMN1; SMN2 1739/4885KDM4E 4319/4885
US-20190055232-A1 NOVEL COMPOUNDS USP30, USP20, USP28 NPC1 2024/4885SMN1; SMN2 3102/4885KDM4E 985/4885
US-20040209936-A1 Compounds that modulate PPAR activity and methods of preparation PPARA, PPARG, PPARD NPC1 117/4885SMN1; SMN2 4864/4885KDM4E 2473/4885
US-20080242665-A1 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; PI4KA, DMPK, PDPK1 NPC1 1004/4885SMN1; SMN2 1408/4885KDM4E 1909/4885
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS ERBB2, ERBB4, ERBB3 NPC1 3053/4885SMN1; SMN2 4711/4885KDM4E 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.